|
|
U.S. Agriculture Biotechnology MarketsPublished by: Frost & Sullivan Published: Nov. 13, 2003 Table of Contents1. Executive Summary 1. Executive Summary 2. Total Market 1. Overview 1. Introduction 2. Report Scope and Segmentation 3. Market Engineering Analysis 2. Forecasts and Trends 1. Overall Trends 2. Demand Analysis 3. Competitive Overview 3. Frost & Sullivan Awards 1. Introduction 2. Market Leadership Award 3. Technology Innovation Award 4. Technology Leadership Award 5. Product Innovation Award 6. Product Differentiation Award 3. Technology and Process 1. Genetically Modified Seeds Development Technology 1. Technology Overview 2. Genetically Modified Traits 2. Plant-made Biologics Production Technologies 1. Technology Overview 2. Technology Profiles of Plant-made Pharmaceutical Production Companies 4. Regulatory Mechanism and Other Strategic Issues 1. Overview of Regulatory Mechanism 1. Approval Process for GM Crops 2. Regulation of Plant-made Pharmaceutical Production - I 3. Regulation of Plant-made Pharmaceutical Production - II 2. Strategic Issues 1. Food Labeling 2. Withdrawn Genetically Modified (GM) Products 3. Health and Environmental Issues of Biotech Crops 4. Adverse Publicity Faced by Biopharming 5. Patent and Intellectual Property 5. Market Opportunity Analysis of Genetically Modified Crops 1. Overview 1. Introduction 2. Scope and Segmentation 3. Genetically Modified Product Analysis 4. Market Engineering Analysis 2. Revenue Forecast for Genetically Modified Crops 1. Revenue Forecast for Chief Crops - I 2. Revenue Forecast for Chief Crops - II 3. Market Challenges a. Prevention of Technology Resistance by Insects b. Constraints of Economic Resources with the Farmers c. Developing Traits that have Direct Appeal to the Food Industry and Consumers d. Getting International Consistent Trade Policy and Regulations for Genetically Modified Crops e. Technical Challenges in Developing New and Improved traits f. Management of Public Relations in U.S. and Other Countries g. Labeling Requirements Specific to Geographical Locations h. Minor crops like Vegetables and Fruits Offer Little Value 4. Market Drivers a. Uncontrollable Weeds and Pests Problems Drive Biotech Crops b. Production Efficiency in Terms of Getting More Yield Due to Better Weeds and Pest Management c. Acceptance by Farmers the Benefits Derived out of Genetically Modified Crops d. Low Till Practices e. Reduced Use of Pesticides Due to the Input Traits for Pest Management f. Growing World Population would Drive the Need for GM Seeds g. Ability of GM Crops for Cultivation in Adverse Environmental Conditions Would Drive Agriculture on Marginalized Land 5. Market Restraints a. Labeling of GM Foods Would Have Adverse Impact on Growth of GM Products b. EU Moratorium on GM Food Imports Hinders Growth c. Concerns over the Transfer of Antibiotics Resistance to Human Beings to Gain Opposition from Public d. Lengthy Development Time and Regulatory Process Would Delay the Growth of this Market e. Opposition to GM Products Slows Down the Acceptance f. Competition by Pesticides and Chemicals Restrains Acceptance g. Product Failures and Withdrawals from Market Impact Growth h. Global Concerns on Nutritional Content Restrain Growth 6. Competitive Structure and Company Profiles 6. Market Opportunity Analysis of Plant-made Pharmaceutical Products 1. Overview 1. Introduction 2. Scope and Segmentation 3. Plant-based Pharmaceutical Product Analysis 4. Market Engineering Analysis 2. Revenue Forecast for Plant Based Pharmaceutical Products 1. Revenue Forecast 2. Market Challenges a. Environmental Containment of Genetically Modified Plant Producing Biologics b. Non-existence of a Plant-based Biologic in the Market Delays Approval c. Lack of Knowledge of the Technology Causes Uncertainty in Obtaining FDA Approval d. Environmentally Challenges such as Weather and Insect Pressure Is a Challenge or Plant-Based Pharmaceutical Production e. Proteins Produced through Plants Are not Glycosylated, Making it Difficult to Produce Complex Proteins 3. Market Drivers a. Multiple Royalty Burdens in Mammalian Cell Culture Systems Drive Alternate Expression Systems b. Relative Ease in Scaling-up Production would Drive the Demand for Biologics Production in Plants c. Safety from Mammalian Viruses and Prions by Plant-Produced Proteins Drives Demand d. Cost Advantage of Biologics Production in Plants Drives Demand e. Capacity Crunch for Biologics Production in Mammalian Cell Culture Systems Drives Demand for Alternate Manufacturing Systems f. Expanding Aging Population is Likely to Increase the Demand for Effective Biologic Drugs for Serious Illnesses such as Cancer, Parkinson’s disease, and Alzheimer’s disease g. Positive Attitude Towards Transgenic Plant Systems for Production of Biologics by Pharmaceutical and Biotech Companies Would Drive Demand 4. Market Restraints a. Stringent U.S. FDA Regulations for Biologics Production Through Transgenic Plants would Delay the Growth of this Market b. Concerns over Food Crops Contamination by Transgenic Crops for Pharmaceutical Production will Have a Negative Impact on the Industry c. The Rapid Success of Transgenic Plant Production Depends on the Anticipated Approvals of Biologics Undergoing Trials 5. Competitive Structure and Company Profiles 7. Appendix 1. Decision Support Database 1. Biological Manufacturing Establishments 2. Biotechnology Employees 3. Number of Biotechnology Companies 4. Pharmaceutical Manufacturing Establishments 5. U.S. Universities List Of Figures Chapter 2 Total Agriculture Biotechnology Market: Area of Genetically Modified Crops (World), 2002 Total Agriculture Biotechnology Market: Global Population Projections (World), 2003-2009 Total Agriculture Biotechnology Market: Revenue Forecasts (U.S.), 1999-2009 Total Agriculture Biotechnology Market: Revenue Forecasts by Segment (U.S.), 1999-2009 Chapter 4 Genetically Modified Crops Market: FDA List of Completed Consultations on Bioengineered Foods (U.S.), 2002 Chapter 5 Genetically Modified Crops Market: Chief Crop Traits for Significant Products (U.S.), 2002 Genetically Modified Crops Market: Revenue Forecasts (U.S.), 1999-2009 Genetically Modified Crops Market: Corn Agriculture Biotechnology Market Forecasts (U.S.), 1999-2009 Genetically Modified Crops Market: Corn Stacked Traits Agriculture Biotechnology Market Forecasts (U.S.), 1999-2009 Genetically Modified Crops Market: Ht Corn Agriculture Biotechnology Market Forecasts (U.S.), 1999-2009 Genetically Modified Crops Market: Bt Corn Agriculture Biotechnology Market Forecasts (U.S.), 1999-2009 Genetically Modified Crops Market: Ht Soybeans Agriculture Biotechnology Market Forecasts (U.S.), 1999-2009 Genetically Modified Crops Market: Cotton Agriculture Biotechnology Market Forecasts (U.S.), 1999-2009 Genetically Modified Crops Market: Bt Cotton Agriculture Biotechnology Market Forecasts (U.S.), 1999-2009 Genetically Modified Crops Market: Cotton Stacked Traits Agriculture Biotechnology Market Forecasts (U.S.), 1999-2009 Genetically Modified Crops Market: Ht Cotton Agriculture Biotechnology Market Forecasts (U.S.), 1999-2009 Genetically Modified Crops Market: Technology/Royalty Fees (U.S.), 2002 Genetically Modified Crops Market: Impact of Top Industry Challenges (U.S.), 2003-2009 Genetically Modified Crops Market: Impact of Top Industry Drivers (U.S.), 2003-2009 Genetically Modified Crops Market: Market Restraints Ranked in Order of Impact (U.S.), 2003-2009 Genetically Modified Crops Market: Competitive Structure (U.S.), 2003 Genetically Modified Crops Market: Profile--Monsanto Company, 2003 Genetically Modified Crops Market: Profile--Dow Agro Sciences, 2003 Genetically Modified Crops Market: Profile--Bayer CropScience, 2003 Genetically Modified Crops Market: Profile--Dupont Crop Protection, 2003 Genetically Modified Crops Market: Profile--Syngenta, 2003 Chapter 6 Plant-Based Pharmaceutical Production Market: Revenue Forecasts (U.S.), 1999-2009 Plant-Based Pharmaceutical Production Market: Impact of Top Industry Challenges (U.S.), 2003-2009 Plant-Based Pharmaceutical Production Market: Market Drivers Ranked In Order Of Impact (U.S.), 2003-2009 Plant-Based Pharmaceutical Production Market: Market Restraints Ranked In Order Of Impact (U.S.), 2003-2009 Plant-Based Pharmaceutical Production Market: Companies--Competitive Structure (U.S.), 2003 Plant-Based Pharmaceutical Production Market: Profile--Biolex, Inc., 2003 Plant-Based Pharmaceutical Production Market: Profile--Dow Plant Biopharmaceuticals, 2003 Plant-Based Pharmaceutical Production Market: Profile--Epicyte Pharmaceutical, 2003 Plant-Based Pharmaceutical Production Market: Profile--Large Scale Biology Corporation, 2003 Plant-Based Pharmaceutical Production Market: Profile--Meristem Therapeutics, 2003 Plant-Based Pharmaceutical Production Market: Profile--Monsanto Protein Technologies, 2003 Plant-Based Pharmaceutical Production Market: Profile--Planet Biotechnologies Inc., 2003 Plant-Based Pharmaceutical Production Market: Profile--Prodigene, 2003 Plant-Based Pharmaceutical Production Market: Profile--SemBioSys Genetics, Inc., 2003 Plant-Based Pharmaceutical Production Market: Profile--Ventria Biosciences, 2003 AbstractA Booming Biopharmaceutical Industry Spurs Agriculture Biotechnology Industry Agriculture biotechnology is gearing up to address the low biologics manufacturing capacity problem in the burgeoning bio-therapeutics industry. Biopharming or plant-based pharmaceutical production involves genetic re-engineering in plants using recombinant DNA techniques to produce pharmaceuticals that treat diseases. Setting up a traditional mammalian cell culture plant requires heavy investments in terms of time and money. Biopharming provides an alternate solution to address the imminent biopharmaceutical manufacturing capacity crunch as the addition of transgenic plants alleviates the production shortage of biologics. This research service analyzes the U.S. Agriculture Biotechnology Markets. This service divides the market into two main segments: genetically modified crop traits and plant-based pharmaceutical production. It provides detailed insights into recent developments, trends, and emerging applications in both. This service also provides competitive and market opportunity analyses. Exploding World Population and Economics of Weed/Pest Management Drive Genetically Modified (GM) Crops A burgeoning global population and shrinking acreage of arable land is making food security a serious concern for developing countries. As huge amounts of crops are lost to pests and weeds, large agriculture research companies are already working on genetically modifying crops to multiply the produce from existing cultivable lands. "The GM crops marketed by agrochemical and biotech companies have stacked traits, which confer them with a built-in resistance to pests, tolerance to herbicides, and high nutritional value," says the analyst. Biotechnology is fast overcoming opposition in many European and Asian countries and by 2006 these countries are likely to irrefutably adopt biotechnology, as necessity drives demand. The revolutionary technology has a huge bearing on agriculture in the United States where a majority of crops are being cultivated using biotechnology to increase yield by better pests and weeds management. "Value-Added Agriculture" to Drive Future Growth "Future development is directed by the introduction of new traits and 'value-added agriculture' where common crop plants such as corn and tobacco are genetically re-programmed to produce high value-add pharmaceuticals and industrial enzymes," says the analyst. Plant-based pharmaceutical technology is at an advanced trail stage and a number of drugs for various diseases - including cancer, fabry disease, and dental caries - are likely to be available for full-fledged production after 2005. Since the energy for the biopharming manufacturing process comes free from natural sources, drugs from plants are potentially less expensive. Therefore, doubling the acreage of a crop requires far less capital than doubling the capacity for factory-made drugs. The cost effectiveness is further giving impetus to the development of plant-based pharmaceutical products that include monoclonal antibodies, recombinant proteins, vaccines, and human enzymes.
|
|
|||
|
About MarketResearch.com
|
||||